radiopharmaceuticals

Telix Pharmaceuticals' Zircaix achieved 98% accuracy in detecting both clear and non-clear cell kidney cancers in Phase 3 trials, expanding its clinical potential and market opportunity.

Telix Pharmaceuticals' glioma imaging candidate TLX101-Px gains European regulatory validation, entering 210-day review phase with potential market approval expected.

Global radiopharmaceuticals market projected to grow from $8.28B (2026) to $15.21B (2035) amid rising cancer and cardiovascular disease incidence.

Radiopharm completes Phase 2b enrollment for brain imaging agent RAD 101 with 90% MRI concordance, initiates new trials while cash reserves fall sharply.

FDA accepts Telix's Pixclara NDA for glioma imaging with September 2026 decision target. Orphan Drug designation provides competitive advantages.

Telix Pharmaceuticals appoints two Non-Executive Directors: former Pfizer CMO Maria Rivas and corporate finance leader William Jellison, effective May 2026.

Radiopharm Theranostics and Siemens Healthineers sign manufacturing supply agreement for RAD101 PET imaging agent, advancing toward Phase 3 trial with strong interim data.

Telix Pharma reports 11% Q1 revenue growth to US$230M, reaffirms FY guidance, while advancing prostate and brain cancer pipelines through Phase 3 and regulatory milestones.

Telix Pharmaceuticals appoints experienced life sciences executive David Gill as Non-Executive Director, with planned succession to Chair role, bringing 35+ years of CFO and commercial expertise.

Telix resubmits FDA application for Pixclara, a brain cancer imaging agent with Orphan Drug and Fast Track designations, addressing a regulatory Complete Response Letter.

Telix Pharmaceuticals' TLX591-Tx meets Phase 3 safety objectives in prostate cancer trial, advancing toward U.S. expansion with FDA.

Telix Pharmaceuticals announces March 2026 webinar on PSMA-PET/CT imaging innovations, featuring leading oncology experts discussing prostate cancer detection advances.

Lantheus posted $1.54B in 2025 revenue but faces Q4 headwinds. The company plans to refocus on PET diagnostics while exploring options for radiotherapy assets, expecting four FDA approvals in 2026.

Telix Pharmaceuticals expands its nuclear medicine presence with approved cancer-targeting drugs and 56% revenue growth, positioning itself as a key player in oncology diagnostics and therapeutics.

Biotech firms advance treatment-resistant cancer therapies across multiple platforms, including oncolytic viruses and cellular immunotherapy, with several candidates achieving regulatory milestones and encouraging clinical data.